...
首页> 外文期刊>Trials >Impact of a pharmacist-led medication review on hospital readmission in a pediatric and elderly population: study protocol for a randomized open-label controlled trial
【24h】

Impact of a pharmacist-led medication review on hospital readmission in a pediatric and elderly population: study protocol for a randomized open-label controlled trial

机译:药剂师主导的药物审查对小儿和老年人群入院的影响:一项随机开放标签对照试验的研究方案

获取原文
           

摘要

Background Early hospital readmission of patients after discharge is a public health problem. One major cause of hospital readmission is dysfunctions in integrated pathways between community and hospital care that can cause adverse drug events. Furthermore, the French ENEIS 2 study showed that 1.3% of hospital stays originated from serious adverse drug events in 2009. Pharmacy-led medication reviews at hospital transitions are an effective means of decreasing medication discrepancies when conducted at admission or discharge. However, it is difficult to assess the true impact of pharmacist-led medication reviews in specific high-risk populations, such as pediatric and geriatric populations. In such a context, it is important to demonstrate the effectiveness of medication reconciliation as part of a standardized medication review process—in pediatric and elderly populations—on all-cause readmissions in a large randomized controlled clinical trial. The aim of this study is to assess the impact of the pharmacist-led medication review on the rate of readmissions and/or death after hospital discharge and patient treatment satisfaction. Methods/design The study is a randomized controlled clinical trial. A total of 1400 hospitalized patients will be randomized in two groups: (1) the experimental group (group receiving a pharmacist-led medication review) and (2) the control group (group receiving usual care). The pharmacist-led medication review process includes medication reconciliation, treatment review and medication liaison service. The primary endpoint will be the rate of readmissions and/or death at 30 days following initial hospitalization discharge. The secondary endpoints will be the rate of hospital readmission, the rate of emergency department visits, the rate of mortality, the number of consultations and patient treatment satisfaction at 30 days following initial hospitalization discharge. Discussion A randomized controlled trial provides the most extensive evidence on the impact of pharmacist-led medication reviews on early hospital readmission for extreme age populations. Trial registration Current Controlled Trials, NCT02734017 . Registered on 4 May 2016.
机译:背景技术出院后患者早期入院是一个公共卫生问题。再次入院的主要原因之一是社区与医院护理之间整合途径的功能障碍,可能导致不良药物事件。此外,法国ENEIS 2研究显示,2009年的住院时间中有1.3%来自严重的不良药物事件。在医院过渡期间,药房主导的药物复审是减少入院或出院时药物差异的有效手段。但是,很难评估由药剂师指导的药物审查对特定的高风险人群(如儿科和老年病人群)的真正影响。在这种情况下,重要的是要在大规模的随机对照临床试验中,针对儿童和老年人群中所有原因的再次入院,证明药物和解作为标准化药物审核过程的一部分是有效的。这项研究的目的是评估药剂师主导的药物审查对出院后再入院和/或死亡率以及患者治疗满意度的影响。方法/设计该研究是一项随机对照临床试验。总共1400名住院患者将被随机分为两组:(1)实验组(接受药剂师指导的药物复习组)和(2)对照组(接受常规护理的组)。由药剂师主导的药物审查过程包括药物对账,治疗审查和药物联络服务。主要终点为首次住院出院后30天的再入院率和/或死亡率。次要终点为首次出院后30天的医院再入院率,急诊就诊率,死亡率,咨询次数和患者治疗满意度。讨论一项随机对照试验提供了最广泛的证据,说明药剂师主导的药物审查对极端年龄人群的早期住院率有影响。试用注册当前控制的试用,NCT02734017。 2016年5月4日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号